Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. (2018)
Attributed to:
Development of a novel drug targeting MRCK and ROCKII for the treatment of invasive and/or metastatic cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1158/0008-5472.can-17-2870
PubMed Identifier: 29382705
Publication URI: http://europepmc.org/abstract/MED/29382705
Type: Journal Article/Review
Volume: 78
Parent Publication: Cancer research
Issue: 8
ISSN: 0008-5472